View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
November 2, 2020

Coronavirus company news summary – Regeneron to stop enrolling critically ill patients into antibody trial – Lonzo and AstraZeneca to partner on antibody drug studies

By Allie Nawrat

2 November 2020 

Regeneron Pharmaceuticals has stopped further enrolment of critically ill hospitalised Covid-19 patients into its antibody drug trial, pending further analysis of the data from already enrolled patients. The independent data monitoring committee, however recommended, enrolment to continue for hospitalised patients requiring no or less oxygen, as well as for outpatient trails of REGN-COV2 without any modification.

Lonza has entered into an agreement with AstraZeneca to develop AZD7442, two long-acting antibodies to treat Covid-19. AZD7442 is currently being studied in Phase I clinical trials, while AstraZeneca plans to advance the two long-acting antibodies into Phase III trials in the coming weeks.

Appili Therapeutics has collaborated with Dr Reddy’s Laboratories and the Global Response Aid to develop and supply Avigan tablets for the treatment of Covid-19. This agreement follows the global licensing transaction between Dr Reddy’s, GRA and FUJIFILM, the inventor of Avigan tablets.

The University of Stanford School of Medicine is set to enrol approximately 1,000 people in a large Phase III trial of a potential vaccine candidate for treating Covid-19. The vaccine is produced by Janssen, a subsidiary of Johnson & Johnson, and this Stanford study will be among a larger trial of 60,000 people across 180 sites globally.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology